Pixelgen builds spatial biology imaging technology for researchers to visualize protein interactions in tissue samples.
$15.5MSeries B
Investor undisclosed
Spatial biology is moving from niche academic tool to commercial infrastructure—a $15.5M Series B signals investors believe the market is past proof-of-concept. Pixelgen is likely using this to scale manufacturing of their imaging hardware and build out a services/SaaS layer around data analysis, which is where the recurring revenue lives. If you're building in biotech tooling or lab automation, watch how they price and distribute—spatial data is becoming table stakes for drug discovery, and whoever owns the workflow (not just the hardware) wins.